이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Caplin Point Laboratories 관리
관리 기준 확인 3/4
Caplin Point Laboratories' CEO는 Sridhar Ganesan, Mar2015 에 임명되었습니다 의 임기는 9.25 년입니다. 총 연간 보상은 ₹ 8.70M, 95.4% 로 구성됩니다. 95.4% 급여 및 4.6% 보너스(회사 주식 및 옵션 포함). 는 ₹ 127.59M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 127.59M. 경영진과 이사회의 평균 재임 기간은 각각 8.3 년과 5.9 년입니다.
주요 정보
Sridhar Ganesan
최고 경영자
₹8.7m
총 보상
| CEO 급여 비율 | 95.4% |
| CEO 임기 | 9.3yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 8.4yrs |
| 이사회 평균 재임 기간 | 6yrs |
최근 관리 업데이트
Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15
We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Recent updates
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Apr 29Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?
Mar 24We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Mar 11Do Caplin Point Laboratories's (NSE:CAPLIPOINT) Earnings Warrant Your Attention?
Feb 26What We Learned About Caplin Point Laboratories' (NSE:CAPLIPOINT) CEO Pay
Feb 14Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Feb 02Can You Imagine How Jubilant Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Feel About Its 105% Share Price Gain?
Jan 21
Does This Valuation Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Imply Investors Are Overpaying?
Jan 09Could The Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Ownership Structure Tell Us Something Useful?
Dec 28Is It Worth Buying Caplin Point Laboratories Limited (NSE:CAPLIPOINT) For Its 0.5% Dividend Yield?
Dec 16We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Dec 04Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Nov 21Here's What We Learned About The CEO Pay At Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Nov 08CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹9m | ₹8m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹3b |
| Jun 30 2022 | n/a | n/a | ₹3b |
| Mar 31 2022 | ₹6m | ₹5m | ₹3b |
| Dec 31 2021 | n/a | n/a | ₹3b |
| Sep 30 2021 | n/a | n/a | ₹3b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹6m | ₹5m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹6m | ₹6m | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹2b |
| Sep 30 2019 | n/a | n/a | ₹2b |
| Jun 30 2019 | n/a | n/a | ₹2b |
| Mar 31 2019 | ₹6m | ₹6m | ₹2b |
| Dec 31 2018 | n/a | n/a | ₹2b |
| Sep 30 2018 | n/a | n/a | ₹2b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹6m | ₹6m | ₹1b |
보상 대 시장: Sridhar 의 총 보상 ($USD 104.19K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 438.56K ).
보상과 수익: Sridhar 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Sridhar Ganesan (69 yo)
9.3yrs
테뉴어
₹8,700,000
보상
Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. He...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD & Whole Time Director | 9.3yrs | ₹8.70m | 0.12% ₹ 132.1m | |
| Chief Financial Officer | 8.4yrs | ₹9.70m | 0.020% ₹ 22.0m | |
| Chief Operating Officer | 12.9yrs | ₹1.90m | 11.84% ₹ 13.1b | |
| General Counsel | 1.9yrs | ₹2.30m | 데이터 없음 | |
| Deputy Chief Financial Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of Marketing - Latam Business | no data | 데이터 없음 | 11.91% ₹ 13.1b | |
| Chief Transformation & Digital Officer | less than a year | 데이터 없음 | 데이터 없음 |
8.4yrs
평균 재임 기간
경험이 풍부한 관리: CAPLIPOINT 의 관리팀은 노련하고 경험 (평균 재직 기간 8.3 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD & Whole Time Director | 10.4yrs | ₹8.70m | 0.12% ₹ 132.1m | |
| Non-Executive Non-Independent Chairman | 34.3yrs | 데이터 없음 | 18.64% ₹ 20.5b | |
| Non-Executive Independent Director | 7.7yrs | ₹160.00k | 데이터 없음 | |
| Non-Executive Independent Director | 4.3yrs | ₹100.00k | 데이터 없음 | |
| Non-Executive Independent Director | 1.8yrs | ₹40.00k | 데이터 없음 | |
| Independent Non-Executive Director | 1.8yrs | ₹60.00k | 0.000090% ₹ 99.2k |
6.0yrs
평균 재임 기간
71.5yo
평균 연령
경험이 풍부한 이사회: CAPLIPOINT 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.